INDUCED PLURIPOTENT STEM CELLS
In 2012, the Nobel Prize in Physiology or Medicine was awarded to John B. Gurdon and Shinya Yamanaka for the discovery that adult differentiated cells can be reprogrammed to become pluripotent and can be used to generate an almost unlimited source of any type of human cell. These cells include cardiac progenitors and terminally differentiated cardiomyocytes, mesenchymal stem cells, endothelial progenitor cells, and vascular smooth muscle cells. 4 The potential of iPSC-CMs to regenerate cardiomyocytes has been recently reviewed in an American Heart Association Consensus Statement that concluded that although cell therapy has potential, among other suggestions, methods of delivery need further study. 5 Although iPSC-CMs can be delivered using injection based modalities, they could also provide building blocks for enhanced delivery approaches, such as engineering a Human Cardiac Patch. 6 
TE FOR CHF
The aim of TE is to overcome the lack of benefit with cell injections that is attributed to poor delivery at the injection site and poor survival, limiting the duration of
ON MY MIND
The Promise of Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Treat Heart Failure functional benefit, which may be because of (1) lack of structural support, and (2) limited nutrient/blood supply and injection site wash out. There are a number of TE approaches that have the potential to deliver iPSC-CMs to the heart. The limited scope of this review does not allow for complete descriptions of all available tissueengineered approaches; however, the most advanced approaches include cell sheets, shape memory scaffolds, tissue decellularization/recellularization, 3-dimensional printing, fibrin, and matrix patches.
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OUR APPROACH
We have developed a TE cardiac graft composed of a bioabsorbable scaffold embedded with fibroblasts and iPSC-CMs that is implanted on the epicardial surface of the heart. The scaffold, paired with fibronectin and collagen extracellular matrix deposits from the fibroblasts, provides matrix support for iPSC-CMs and a robust structure permitting handling and manipulation during surgical implantation. In preclinical models of CHF, the graft reverses maladaptive left ventricular remodeling, activates endogenous growth factor secretion, and improves myocyte density, left ventricular systolic and diastolic function, electrical propagation, myocardial blood flow, and is not proarrhythmic.
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AUTOLOGOUS VERSUS ALLOGENEIC
The initial approach to cell therapy proposed utilizing autologous cells for cell survival without the need for immune suppression. The downside of autologous approaches is that cell collection and processing to create a patient-specific product is time consuming and costly. Stability of the lines, especially from older donors needs to be considered as in the autologous iPSC macular degeneration trial in Japan that now using allogeneic cells. 16 Allogeneic cells can improve safety and potency by using healthy donors and decrease costs to improve availability by manufacturing in bulk.
IMMUNE SUPPRESSION
The currently active Japanese CHF trial administers allogeneic iPSC-CMs with immune suppression. The use of immune suppression is based on the belief that human iPSC-CMs are not immune privileged and the need for long-term cell survival. 17 There is evidence of lack of engraftment even with immune suppression. 11 An approach to potentially avoid immune suppression is to develop cell banks from donors with known human leukocyte antigens and then match donor iPSCs with recipients. The necessity to maintain human leukocyte antigens cell banks and generate products from each bank would be expensive, limiting its appeal. It is also possible to use gene editing to create iPSCs with reduced cell surface markers to limit or diminish an immune response (http:// www.universalcells.com/technology). It is unclear if either of these approaches will result in cell survival. Furthermore, some investigators believe that cell survival is not required for functional benefit, but there are minimal data to support this. We need to understand the immunologic profiles and mechanisms of action of cells to determine if immune suppression is needed and, if so, the appropriate regimen for clinical trials. 17 We believe that duration of benefit can outlast cell survival and the duration of cell survival required may be application specific.
MECHANISM OF ACTION
A criticism of work with iPSC-CM cell therapy is that we do not understand the mechanisms of action of these cells in treating CHF. Most investigators favor paracrine effects, such as growth factor/cytokine secretion and possibly exosomes generated from iPSC-derivatives. 18 The specific paracrine stimulation profile may vary by cell type and be unique to the delivery approach. There are other challenges of cardiac TE, including the need to understand which cell or combination of cells are needed, how to provide vascularization of the tissue, and how to support cell integration into these platforms. 19 Suggestions have been made that we should not proceed into clinical trials until we have a better understanding of mechanisms of action. It is important to remember that drugs for CHF, such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenergic receptor blockers were approved without knowing their specific mechanisms in CHF.
CONCLUSIONS
Although there is still much work to be done to achieve optimal functional benefit, the investigators in Japan using iPSC-CMs to treat patients with CHF are to be congratulated for moving the field forward. 
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